

What is claimed is:

1. A method for the treatment of irritation or disorders of the nose and eye which comprises applying directly to nasal tissues or to the conjunctival sac of the eye a medicament which contains a member of the group consisting of azelastine and its physiologically acceptable salts.
2. A method as set forth in claim 1 in which the medicament contains 0.0005 to 2% (weight/weight) of azelastine.
3. A method as set forth in claim 2 in which the medicament contains 0.001 to 1% (weight/weight) azelastine.
4. A method as set forth in claim 3 in which the medicament contains 0.003 to 0.5% (weight/weight) azelastine.
5. A method as set forth in claim 1 in which the medicament contains a pharmaceutically usable preservative in an amount of 0.001 to 0.1%.
6. A method as set forth in claim 1 in which the medicament is a solution.
7. A method as set forth in claim 1 in which the medicament is an aqueous solution.
8. A method as set forth in claim 1 in which the medicament is a solution which contains 0.001 to 0.05% (weight/volume of solution) of sodium-2-(ethylmercurithio)-benzoate or 0.001 to 0.1% (weight/volume of solution) of alkylbenzyltrimethyl ammonium chloride.
9. A method as set forth in claim 1 in which the medicament is applied by spraying.
10. A method as set forth in claim 1 in which the medicament is applied as drops.
11. A method as set forth in claim 1 in which the medicament is a powder.

Sub
B2

12. A method of treating a patient suffering from allergy-related, or vasomotor or rhino virus-related colds or symptoms which comprises applying directly to the patient's nasal tissues or to the conjunctival sac of the patient's eye a medicament which contains a member of the group consisting of azelastine and its physiologically acceptable salts.

13. A dispensing container containing an eye dropper, said container also containing a solution of azelastine or a physiologically acceptable salt of azelastine.

14. An atomizing container having a pump sprayer, said container containing a solution of azelastine or a physiologically acceptable salt of azelastine.

15. A compressed gas atomizing container having a valve constructed and arranged to release a predetermined amount of a atomized liquid upon each actuation, said container containing a propellant and a solution ^(or suspension) of azelastine or a physiologically acceptable salt of azelastine.

16. A compressed gas atomizing container as set forth in claim 15 in which the concentration of azelastine or a physiologically acceptable salt of azelastine is such that 0.03 to 3 mg of azelastine is released upon each actuation of said valve.

17. A dispensing tube containing an ointment, said ointment containing azelastine or a physiologically acceptable salt of azelastine.

18. Powder containing 0.0005 to 2% of azelastine or a physiologically acceptable salt of azelastine as active agent together with conventional pharmaceutical carrier substances.